Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 ...

Aktis Oncology (AKTS) stock surged after an upsized Nasdaq IPO aimed at raising ~$318M with the help of its partner Eli Lilly ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

Investing.com -- Aktis Oncology Inc. has increased the size of its initial public offering by 50% and secured interest from Eli Lilly & Co. for $100 million of shares in the listing.

Aktis Oncology (AKTS) stock is in focus as the company which counts Eli Lilly (LLY) among its partner seeks up to $840M in ...

Backed by Eli Lilly, Aktis Oncology's $318M IPO marks 2026's first major biotech public offering, signaling renewed investor ...

InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...